Premium
Interleukin‐10 inhibits autonomous myelopoiesis in patients with myelofibrosis
Author(s) -
Geissler Klaus,
Jäger Eva,
Öhler Leopold,
Gisslinger Heinz,
Jäger Ulrich,
Lechner Klaus
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12486
Subject(s) - myelopoiesis , haematopoiesis , myelofibrosis , cytokine , peripheral blood mononuclear cell , immunology , in vitro , myeloid , granulocyte , biology , microbiology and biotechnology , stem cell , biochemistry , bone marrow
The spontaneous formation of colony‐forming units granulocyte/macrophage (CFU‐GM) in semisolid cultures has been shown to be due to the endogenous release of cytokines and/or to the hypersensitivity of cells against growth factors. We have reported that increased autonomous CFU‐GM growth is an in vitro characteristic of myelofibrosis (MF) which may reflect aberrant hematopoiesis in vivo . Because of its cytokine synthesis‐inhibiting action, we speculated that interleukin‐10 (IL‐10) may inhibit pathological overproduction of myeloid cells in MF by suppression of autonomous myelopoiesis. In this study, IL‐10 significantly inhibited autonomous CFU‐GM formation in vitro from peripheral blood mononuclear cells (PB MNC) in 10 of 11 patients with MF tested. In all patients, there was a mean inhibition of 69% ranging from 35% to 100%. Suppression of autonomous CFU‐GM formation by IL‐10 was dose dependent and reversible by the addition of anti‐IL‐10 antibodies. Our results indicate that IL‐10 is a potentially useful molecule to affect aberrant myelopoiesis in patients with MF.